SEC Filing Summary for Immunovant, Inc.

On April 8, 2026, Jay Stout, Chief Technology Officer of Immunovant, Inc., sold 8,614 shares of Common Stock at a price of $24.83 per share, totaling $213,817.02. This transaction was made to cover tax withholding obligations related to the vesting of 19,045 restricted stock units (RSUs) granted on April 1, 2025. The sale was mandated by the company to satisfy tax withholding, and it does not represent a discretionary transaction. Additionally, on the same date, another sale of 1,518 shares of Common Stock at $24.83 per share was made by the reporting person, also to cover tax withholding obligations. This sale was related to the vesting of 3,436 RSUs granted on April 2, 2024. The prices reported are weighted averages, with sales occurring in the range of $24.54 to $25.39 per share. Following these transactions, Stout’s post-transaction share ownership is 254,439 shares.